BriaCell Therapeutics Corp. (NASDAQ:BCTX)

BriaCell Therapeutics Corp. BCTX

Healthcare - Biotechnology - NASDAQ - CA

Watchlist

$ 0.595

0 %

$ 21.5 M

Market Cap

-2.05

P/E

1. INTRINSIC VALUE

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.[ Read More ]

The intrinsic value of one BCTX stock under the base case scenario is HIDDEN Compared to the current market price of 0.595 USD, BriaCell Therapeutics Corp. is HIDDEN

BCTX Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart BCTX

FINANCIALS

Annual
Quarterly

0 REVENUE

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-32.8 M OPERATING INCOME

Growth Rates

1Year -40.98%

3Years -114.66%

5Years -104.39%

7Years -43.79%

10Years -54.00%

-4.93 M NET INCOME

Growth Rates

1Year 75.71%

3Years -125.81%

5Years -2.29%

7Years -9.67%

10Years 4.90%

-24.1 M OPERATING CASH FLOW

Growth Rates

1Year -1.61%

3Years -46.03%

5Years -44.16%

7Years -48.22%

10Years -52.10%

-682 K INVESTING CASH FLOW

Growth Rates

1Year 0.00%

3Years 0.00%

5Years -10.78%

7Years -31.13%

10Years -13.83%

4.42 M FINANCING CASH FLOW

Growth Rates

1Year 11.75%

3Years -59.19%

5Years 14.17%

7Years 9.61%

10Years 10.70%

22.7 K REVENUE

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-5.77 M OPERATING INCOME

Growth Rates

1Year -40.98%

3Years -114.66%

5Years -104.39%

7Years -43.79%

10Years -54.00%

-1.2 M NET INCOME

Growth Rates

1Year 75.71%

3Years -125.81%

5Years -2.29%

7Years -9.67%

10Years 4.90%

-4.11 M OPERATING CASH FLOW

Growth Rates

1Year -1.61%

3Years -46.03%

5Years -44.16%

7Years -48.22%

10Years -52.10%

-457 K INVESTING CASH FLOW

Growth Rates

1Year 0.00%

3Years 0.00%

5Years -10.78%

7Years -31.13%

10Years -13.83%

4.42 M FINANCING CASH FLOW

Growth Rates

1Year 11.75%

3Years -59.19%

5Years 14.17%

7Years 9.61%

10Years 10.70%

Balance Sheet Decomposition BriaCell Therapeutics Corp.

5.87 M ASSETS
8.56 M LIABILITIES

Current Assets	3.65 M
Cash & Short-Term Investments	862 K
Receivables	1.37 M
Other Current Assets	1.42 M
Non-Current Assets	2.22 M
Long-Term Investments	419 K
PP&E	388 K
Other Non-Current Assets	1.41 M

Current Liabilities	7.46 M
Accounts Payable	7.17 M
Short-Term Debt	0
Other Current Liabilities	290 K
Non-Current Liabilities	1.1 M
Long-Term Debt	0
Other Non-Current Liabilities	1.1 M

EFFICIENCY

Earnings Waterfall BriaCell Therapeutics Corp.

Revenue	0
Cost Of Revenue	82.6 K
Gross Profit	-82.6 K
Operating Expenses	32.7 M
Operating Income	-32.8 M
Other Expenses	-27.9 M
Net Income	-4.93 M

RATIOS

0.00% GROSS MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

0.00% OPERATING MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

0.00% NET MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

201.03% ROE

Averages

1Year 201.03%

3Years 208.81%

5Years 115.87%

7Years 85.48%

10Years -19.29%

-81.59% ROA

Averages

1Year -81.59%

3Years -61.18%

5Years 20.19%

7Years 41.80%

10Years -27.83%

1394.58% ROIC

Averages

1Year 1394.58%

3Years 619.22%

5Years 361.02%

7Years 245.80%

10Years 79.20%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis BriaCell Therapeutics Corp.

Net Income	-4.93 M
Depreciation & Amortization	83.9 K
Capital Expenditures	-457 K
Stock-Based Compensation	1.8 M
Change in Working Capital	6.94 M
Others	-27.1 M
Free Cash Flow	-24.6 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets BriaCell Therapeutics Corp.

BCTX has no price targets from Wall Street.

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.

0.23 USD

XFOR

Overvalued 42.95%

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.

1.11 USD

TERN

Overvalued 81.96%

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

2.89 USD

DAWN

Overvalued 78.30%

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.

1.06 USD

PDSB

Overvalued 47.42%

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases.

-0.232 USD

INZY

Overvalued 107.41%

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer.

-2.09 USD

EFTR

Overvalued 1044932.22%

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States.

0.561 USD

ELEV

Undervalued 5.55%

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally.

-0.0218 USD

MREO

Overvalued 100.62%

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.

3.67 USD

HEPA

Undervalued 439.85%

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.

3.56 USD

HOOK

Undervalued 18.58%

6. Ownership

Insider Ownership BriaCell Therapeutics Corp.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

3.91 M USD 1

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
6 months ago May 14, 2024	Bought 2 M USD	Lustig Marc director, 10 percent owner:	+ 902935	2.215 USD
6 months ago May 14, 2024	Bought 1.91 M USD	Lustig Marc director, 10 percent owner:	+ 902935	2.11 USD
1 year ago Dec 28, 2022	Bought 128 K USD	Bondarenko Jamieson Chairman	+ 28000	4.58 USD
1 year ago Dec 23, 2022	Bought 4.91 K USD	Williams William V. President, CEO	+ 2530	1.94 USD
1 year ago Dec 20, 2022	Bought 118 K USD	Bondarenko Jamieson Director	+ 22000	5.35 USD

7. News

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-BRES+™ and Bria-PROS+™, respectively, during a poster session at the 2024 Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX. globenewswire.com - 1 week ago

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13 PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces five posters, including a Spotlight poster presentation, at the San Antonio Breast Cancer Symposium® (SABCS®) 47th Annual Meeting, being held December 10 – 13 , 2024, at the Henry B. Gonzalez Convention Center, San Antonio, Texas. globenewswire.com - 1 week ago

BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns BriaCell Therapeutics' lead candidate, Bria-IMT, shows promising trial results for metastatic breast cancer, potentially doubling overall survival and median progression-free survival. Despite a market cap below $30 million, BriaCell could tap into a $1-$5 billion market upon approval, with valuations between $1-$2 billion. Financing and shareholder dilution remain significant concerns, with recent offerings raising $18.5 million but also massively increasing the share count. seekingalpha.com - 3 weeks ago

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data PHILADELPHIA and VANCOUVER, British Columbia, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, outperforming patients, and survival rates in its Phase 2 metastatic breast cancer (MBC) study. globenewswire.com - 3 weeks ago

BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study PHILADELPHIA and VANCOUVER, British Columbia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today provides a clinical engagement update of its pivotal Phase 3 study of Bria-IMT™ in combination with immune check point inhibitor in metastatic breast cancer (MBC). The study will enroll up to 354 patients randomized 1:1 to the BriaCell combination regimen or physician's choice and will include a small number (n=50) of patients randomized to Bria-IMT™ monotherapy. globenewswire.com - 1 month ago

BriaCell Therapeutics Announces Closing of $5 Million Offering PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts offering of 5,128,500 common shares and warrants to purchase up to 5,128,500 common shares at a combined offering price of $0.975 per share and associated warrant, priced at-the-market under Nasdaq rules. The warrants have an exercise price of $0.85 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are approximately $5 million. globenewswire.com - 1 month ago

BriaCell Therapeutics Announces $5 Million Offering PHILADELPHIA and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 5,128,500 common shares and warrants to purchase up to 5,128,500 common shares at a combined offering price of $0.975 per share and associated warrant, priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $0.85 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. globenewswire.com - 1 month ago

BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor PHILADELPHIA and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report dramatic anti-tumor response including complete resolution of temporal lobe breast cancer metastasis in a patient treated in the Phase 2 study of BriaCell's Bria-IMT™ plus an immune checkpoint inhibitor regimen. The patient demonstrated an initial partial response at 2 months in the brain lesion with no detectable disease following 8 and 11 months of treatment. globenewswire.com - 1 month ago

What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 month ago

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients PHILADELPHIA and VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce U.S. FDA (FDA) authorization of an Expanded Access Policy (EAP) for metastatic breast cancer (MBC) patients. globenewswire.com - 1 month ago

BriaCell Therapeutics Announces Closing of $8.5 Million Offering PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts offering priced at-the-market under Nasdaq rules for 12,325,000 common shares. Each common share was sold at an offering price of $0.69 per share, for gross proceeds of approximately $8.5 million, before deducting placement agent fees and other offering expenses. All the shares in the offering were offered by the Company. globenewswire.com - 2 months ago

Penny Stocks On the Move (CNEY, BCTX, FTCI, TANH, QH) If you're a penny stock trader or investor, you likely look for the most active stocks in the category from time to time. 247wallst.com - 2 months ago

8. Profile Summary

BriaCell Therapeutics Corp. BCTX

COUNTRY CA

INDUSTRY Biotechnology

MARKET CAP $ 21.5 M

Dividend Yield 0.00%

Description BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Contact Bellevue Centre, West Vancouver, BC, V7T 2X1 https://www.briacell.com

IPO Date March 14, 2012

Employees 16

Officers Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. Chief Financial Officer & Corporate Secretary Dr. Miguel A. Lopez-Lago Ph.D. Chief Scientific Officer Dr. William V. Williams M.D. Chief Executive Officer, President & Director Dr. Charles Louis Wiseman FACP, M.D. Founder, Principal Research Advisor & Member of Scientific Advisory Board Dr. Giuseppe Del Priore M.D., M.P.H., MPH Chief Medical Officer

Price Chart BCTX

BriaCell Therapeutics Corp. BCTX

Premium Plan

Unlimited Plan